MapLight Therapeutics (MPLT) CFO Gillis Sells $82K of Stock

Jonathan Gillis, Chief Accounting Officer and Interim CFO of MapLight Therapeutics, Inc. (NasdaqGS: MPLT), sold 10,167 shares of company stock on October 15, 2026, according to a Form 4 filing with the Securities and Exchange Commission.

Inside Jonathan Gillis's MPLT Trade

Gillis executed the sale at a price of $8.08 per share, bringing the total value of the transaction to $82,149.36. The stock closed at $8.02 on the day of the trade. This transaction follows several other insider sales at the biotechnology firm during October 2026.

Other Institutional Activity in MapLight Therapeutics

Novo Holdings A/S held steady with 3,686,622 shares valued at about $28,386,988 in its report filed for June 30, 2026. FCPM III Services B.V. kept its holding unchanged at 3,226,400 shares worth about $24,843,279. Nan Fung Group Holdings Limited maintained its stake of 971,253 shares valued at roughly $7,478,647. 5AM Venture Management, LLC held 950,011 shares worth about $7,315,084. Sanofi kept its position at 912,041 shares valued around $7,022,715.

MapLight Therapeutics, Inc. Stock Down 3.9%

The shares recently traded around $7.71 as of October 16, 2026, down about 3.9% from the event-day close. The stock has experienced a sharp decline over the past year, sitting well below its 50-day moving average and far from its 52-week high of $40.43.

Recent Earnings

The company reported trailing-twelve-month earnings per share of -$6.25 and a return on equity of -111.5%. Its next financial update is scheduled for November 12, 2026.

Insider Buying and Selling at MapLight Therapeutics, Inc.

Insider activity has picked up recently. On July 28, 2026, director Troy M Cox bought 15,620 shares at $12.31 each for a total of $192,282. Beneficial owner Catalyst4 bought 1,209,225 shares on July 30, 2026, and another 4,400,000 shares at $11.38 on August 14, 2026, worth $50,072,000. Meanwhile, officer James Woodruff Lillie sold 22,082 shares at $12.54 on August 3, 2026, for $276,908. These trades join recent October sales by other members of the executive team.

Analysts Set New Price Targets

Wall Street firms have adjusted their expectations heading toward late 2026. On July 28, 2026, Canaccord Genuity maintained a buy rating while lowering its price target to $24.00 from $43.00. On the same day, Morgan Stanley downgraded the stock to equal-weight and trimmed its target to $21.00 from $34.00. UBS followed on August 10, 2026, with a downgrade to neutral and a reduced target of $13.00. Needham maintained a buy rating on August 31, 2026, adjusting its target from $45.00 to $43.00. Guggenheim initiated coverage with a neutral rating on October 6, 2026. Overall, the stock carries a consensus strong buy rating backed by 13 analyst opinions and a mean price target of $26.54.

About MapLight Therapeutics

Headquartered in Redwood City, California, MapLight Therapeutics operates as a clinical-stage biopharmaceutical company focused on developing treatments for patients suffering from severe central nervous system disorders. The company employs 133 people and advances a pipeline of novel therapeutic candidates.

Bottom Line

Investors will watch the upcoming earnings report on November 12, 2026, for updates on clinical progress and cash burn. Further Form 4 filings will show whether executive selling continues through the end of the quarter.